Samsung to enter biosimilars market

Biosimilars/News | Posted 25/03/2011 post-comment0 Post your comment

Everybody is jumping on the biosimilars bandwagon these days, and it seems it is not just limited to pharmaceutical companies. Contract research organisation, Quintiles, announced on 28 February 2011 that it has entered into a deal with electronics giant Samsung to provide biologicals manufacturing and biosimilar development.

picture29

Under the agreement, Quintiles will make a minority 10% investment of approximately US$30 million to start the new joint venture with the Seoul-based Samsung Group, which will provide biopharmaceutical contract manufacturing services in South Korea.

Samsung will begin construction of a new manufacturing facility near Seoul, South Korea, later in 2011; and plans to sell its first biological products by 2013. Biosimilars, starting with the cancer and rheumatoid arthritis treatment, rituximab (Rituxan), are expected to be in production by 2016.

The investment will help the Samsung Group enter the lucrative biologicals market, which already boasts five of the world’s top 10 bestselling medicines. The Seoul-based group may exceed its target to generate US$1.8 trillion a year by 2020 from biopharmaceuticals because of the demand for those medicines, Samsung Executive Vice President Mr Kim Tae Han told Bloomberg.

Related article

Biosimilars boost for South Korea

Source: Bloomberg, Quintiles

comment icon Comments (0)
Post your comment
Related content
Canada approves adalimumab and bevacizumab biosimilars
Health Canada V13I20
Biosimilars/News Posted 22/10/2021
EMA recommends approval of two adalimumab biosimilars
ST002293
Biosimilars/News Posted 01/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010